478149-02-9

Usage

Uses

Used in Pharmaceutical Industry:
Thieno[3,2-b]pyridine-2-carboxylic acid methyl ester is utilized as a key building block in the synthesis of pharmaceutical compounds. Its distinctive structure allows it to modulate biological targets, making it a promising candidate for the development of new drugs to treat a variety of medical conditions.
Used in Organic Chemistry:
In the realm of organic chemistry, Thieno[3,2-b]pyridine-2-carboxylic acid methyl ester serves as an important intermediate for the synthesis of complex organic molecules. Its heterocyclic nature and reactivity contribute to the creation of novel compounds with potential applications in various chemical processes.
Used in Drug Discovery and Development:
Due to its ability to interact with biological targets, Thieno[3,2-b]pyridine-2-carboxylic acid methyl ester is employed in drug discovery and development. Researchers leverage its structural features to design and optimize new therapeutic agents that can address unmet medical needs.
Used in the Study of Heterocyclic Compounds:
Thieno[3,2-b]pyridine-2-carboxylic acid methyl ester is also used in academic and research settings to further the understanding of heterocyclic compounds. Its synthesis and reactions provide insights into the chemistry of these complex molecules, potentially leading to new discoveries and applications.

Upstream product

• 31224-43-8 3-fluoropyridine-2-carbaldehyde 
• 2365-48-2 Methyl thioglycolate 
• 38180-46-0 3-chloro-2-cyanopyridine 
• 111042-90-1 methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylate 

Downstream Products

• 94191-19-2 2-hydroxymethylthieno<3,2-b>pyridine 

Relevant academic research and scientific papers

MODULATORS OF THE NMDA RECEPTOR

The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease

The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I: 1where in W is 2These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which α7 is known to be involved.